Bioresorbable Vascular Scaffold Market Size worth $790.26 Million by 2032 | CAGR: 8.89%

The global Bioresorbable Vascular Scaffold Market is expected to grow at growth rate of 8.89% to reach USD 790.26 Million by 2032.

Bioresorbable scaffolds (BRS) provide the immediate benefits of permanent stents while offering the distinct advantage of complete degradation over time. This gradual breakdown helps restore vasomotor and endothelial functions, supporting long-term vascular healing. Bioresorbable Vascular Scaffolds (BVS) represent a major advancement in coronary artery disease treatment, delivering temporary arterial support while eliminating the long-term presence of traditional implants. However, ongoing research and clinical trials remain essential to enhance their safety and efficacy, positioning BRS as a promising yet evolving technology in cardiovascular medicine.

The rising prevalence of cardiovascular diseases (CVDs) and the growing demand for minimally invasive treatments are key drivers of market expansion. CVDs, including coronary artery disease (CAD), heart attacks, and strokes, are becoming increasingly common, particularly among aging populations and individuals with risk factors such as hypertension, diabetes, obesity, and physical inactivity. According to the World Health Organization (WHO), CVDs are the leading cause of death globally, accounting for approximately 17.9 million deaths annually. Bioresorbable vascular scaffolds (BVS) are playing a growing role in percutaneous coronary interventions (PCI), providing a less invasive solution for treating arterial blockages. Additionally, continuous advancements in BVS design, materials, and functionality are unlocking new opportunities for market growth. While challenges related to manufacturing and scalability persist, they also create pathways for innovation and industry development.

Request Sample Copy of Report: Bioresorbable Vascular Scaffold Market

North America dominates the Bioresorbable Vascular Scaffold (BVS) market, driven by its advanced healthcare infrastructure and continuous medical innovation. The region boasts state-of-the-art hospitals and specialized cardiovascular centers, making it well-equipped to adopt cutting-edge treatment options such as bioresorbable vascular scaffolds. The United States stands out as a hub for medical advancements and technological progress. A 2023 survey by Morning Consult revealed that 40% of U.S. adults use healthcare-related applications, while 35% rely on wearable healthcare devices, highlighting the region’s strong embrace of digital health solutions. Meanwhile, the Asia-Pacific region presents significant growth potential, fueled by rising healthcare investments and growing demand for innovative treatment solutions. However, economic disparities and cost-related challenges in developing regions like Latin America and Africa may hinder the widespread adoption of BVS technology.

KEY BENEFITS OF THE REPORT:

• Insights into strategies adopted by key players to maintain competitiveness.
• Comprehensive analysis of the leading companies shaping the competitive landscape.
• Examination of the key drivers fuelling global market growth.
• Identification of the geographic regions expected to experience the highest growth.
• Detailed evaluation of the current market conditions and future growth projections.

The Bioresorbable Vascular Scaffold (BVS) market is highly competitive, with leading companies focusing on advancements in materials, coating technologies, and design innovations to enhance product performance. The development of safer, more effective, and faster-dissolving stents remains a key priority, as manufacturers seek to improve patient outcomes and address long-term concerns associated with traditional stents. While innovation in drug-eluting capabilities, design enhancements, and biocompatible materials continues to drive market growth, clinical outcomes, safety concerns, and regulatory hurdles will play a crucial role in shaping competition within the industry. April 29, 2024 – Abbott received FDA approval for the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System). This groundbreaking technology represents a major advancement for individuals with chronic limb-threatening ischemia (CLTI) below the knee (BTK). The Esprit BTK System is designed to maintain arterial patency while delivering Everolimus, a drug that promotes vascular healing before the scaffold fully dissolves.

The scope of this report covers the market by its major segments, which include as follows:

Market Segmentation

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BIORESORBABLE VASCULAR SCAFFOLD MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Ø Abbott

Ø Kyoto Medical

Ø Biotronik

Ø Elixir Medical (MedImpact Healthcare Systems, Inc.)

Ø C. R. Bard, Inc. (Becton, Dickinson, and Company)

Ø Teleflex Incorporated

Ø B. Braun Melsungen AG

Ø Medtronic

Ø Argon Medical Devices, Inc

Ø Others

GLOBAL BIORESORBABLE VASCULAR SCAFFOLD MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

Ø Drug-eluting coronary scaffolds

Ø Everolimus-eluting device

Ø Novolimus-eluting device

Ø Sirolimus-eluting device

Ø Paclitaxel-eluting device

GLOBAL BIORESORBABLE VASCULAR SCAFFOLD MARKET, BY MATERIAL TYPE- MARKET ANALYSIS, 2019 - 2032

Ø Poly-L-Lactic Acid(PLLA)

Ø Tyrosine-Derived Polycarbonate

Ø Others

GLOBAL BIORESORBABLE VASCULAR SCAFFOLD MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

Ø Peripheral Artery

Ø Coronary Artery

GLOBAL BIORESORBABLE VASCULAR SCAFFOLD MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Ø Hospitals

Ø Ambulatory Care Centers (ACS)

Ø Specialty Clinics

GLOBAL BIORESORBABLE VASCULAR SCAFFOLD MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America

U.S.

Canada

Europe

Germany

Uk

France

Italy

Spain

The Netherlands

Sweden

Russia

Poland

Rest Of Europe

Asia Pacific

China

India

Japan

South Korea

Australia

Indonesia

Thailand

Philippines

Rest Of Apac

Latin America

Brazil

Mexico

Argentina

Colombia

Rest Of Latam

The Middle East And Africa

Saudi Arabia

Uae

Israel

Turkey

Algeria

Egypt

Rest Of Mea

o Algeria

o Egypt

o Rest of MEA